Oncolytics Biotech Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CONTANGO who started this subject	4/18/2002 8:24:07 AM
From: geoffb_si	of 103

Pfizer(?) results in animal treatment. Results look good, especially with no pre-screening for RAS-activated cancer or determination of best dose schedule. In any case, Oncolytics remains focused on Human Trials. ---------------------------- Oncolytics Biotech Reports REOLYSIN(R) Canine Study Results CALGARY, April 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSE: ONC, NASDAQ: ONCY) ('Oncolytics') reported results from a study conducted by a third party examining the use of REOLYSIN® in canines (companion pet dogs) with naturally occurring cancers. ``REOLYSIN® has again demonstrated safety and efficacy that is consistent with the other animal models and the promising human clinical studies that we have conducted to date,'' said Dr. Brad Thompson, President and CEO of Oncolytics. ``We continue to be focussed on the execution of our clinical strategy to develop REOLYSIN® as quickly as possible on the basis of a carefully planned series of clinical programs.'' The study examined the effect of three injections of REOLYSIN® administered on alternating days directly into a subcutaneous (underneath the skin) malignant tumour in 17 canines. Efficacy was assessed by both measurement of tumour response and by histopathological comparison of pre-treatment and post-treatment tumour biopsies (comparison of tissue samples). Canines were considered to be evaluable for tumour response only if they were available for all follow-ups. None of the animals were screened for RAS activation of their tumours prior to enrolment. In six of fifteen evaluable canines, the injected tumours were classified as stable disease (five) or partial responses (one) on day 32 after the first injection of REOLYSIN®. Fifteen of seventeen cases were evaluable by histopathology, where tumour necrosis (cell death) is the primary indication of efficacy in cancer therapy. Nine of fifteen (60%) post-treatment biopsies from tumour masses showed increased cell death. Two of the treated tumour masses appeared to be completely replaced by non-cancerous cells and fibrous tissue and another four cases had evidence of cell death in at least 75% of the biopsy sample. The safety of REOLYSIN® was examined in all dogs and there were no serious adverse reactions related to the treatment. About Oncolytics Biotech Inc. . . .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next